Insufficient scRNA-seq data for expression of UBA7 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 6843.64 | 652 / 653 | 100% | 52.86 | 605 / 605 |
ovary | 100% | 6237.91 | 180 / 180 | 98% | 46.44 | 422 / 430 |
stomach | 100% | 3784.53 | 359 / 359 | 98% | 31.92 | 280 / 286 |
kidney | 100% | 4578.89 | 89 / 89 | 98% | 33.85 | 881 / 901 |
intestine | 100% | 6157.61 | 966 / 966 | 97% | 33.41 | 513 / 527 |
uterus | 100% | 5627.41 | 170 / 170 | 96% | 42.41 | 440 / 459 |
bladder | 100% | 4473.95 | 21 / 21 | 96% | 40.11 | 483 / 504 |
pancreas | 97% | 1919.52 | 319 / 328 | 98% | 45.97 | 175 / 178 |
lung | 100% | 7072.76 | 578 / 578 | 95% | 32.69 | 1102 / 1155 |
breast | 99% | 4444.07 | 456 / 459 | 96% | 34.93 | 1074 / 1118 |
prostate | 100% | 7160.01 | 245 / 245 | 94% | 27.34 | 473 / 502 |
liver | 96% | 2237.06 | 216 / 226 | 96% | 27.79 | 388 / 406 |
adrenal gland | 100% | 3881.48 | 258 / 258 | 91% | 23.47 | 209 / 230 |
esophagus | 100% | 3560.16 | 1441 / 1445 | 90% | 25.79 | 164 / 183 |
skin | 97% | 2181.25 | 1754 / 1809 | 87% | 36.95 | 410 / 472 |
brain | 56% | 728.04 | 1484 / 2642 | 97% | 27.56 | 681 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 64.40 | 29 / 29 |
spleen | 100% | 12629.84 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.24 | 1 / 1 |
adipose | 100% | 4153.12 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4054.35 | 1330 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 5213.34 | 916 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 45.30 | 43 / 45 |
heart | 93% | 2008.43 | 805 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 59% | 13.87 | 47 / 80 |
muscle | 33% | 383.00 | 268 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0016567 | Biological process | protein ubiquitination |
GO_0032020 | Biological process | ISG15-protein conjugation |
GO_0036211 | Biological process | protein modification process |
GO_0045087 | Biological process | innate immune response |
GO_0019941 | Biological process | modification-dependent protein catabolic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0019782 | Molecular function | ISG15 activating enzyme activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | UBA7 |
Protein name | Ubiquitin-like modifier-activating enzyme 7 (Ubiquitin-activating enzyme 7) (EC 6.2.1.-) (D8) (Ubiquitin-activating enzyme E1 homolog) |
Synonyms | UBE2 UBE1L |
Description | FUNCTION: E1-activating enzyme that catalyzes the covalent conjugation of the ubiquitin-like protein product of ISG15 to additional interferon stimulated proteins (ISGs) as well as other cellular proteins such as P53 in a process termed protein ISGylation . Plays an essential role in antiviral immunity together with ISG15 by restricting the replication of many viruses including rabies virus, influenza virus, sindbis virus, rotavirus or human cytomegalovirus . For example, ISG15 modification of influenza A protein NS1 disrupts the association of the NS1 with importin-alpha leading to NS1 nuclear import inhibition . ISGylation of human cytomegalovirs protein UL26 regulates its stability and inhibits its activities to suppress NF-kappa-B signaling . . |
Accessions | P41226 ENST00000333486.4 |